Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.56 |
| ▸ | SLC1A1 | P43005 | 5/20 | 0.52 |
| ▸ | SLC1A3 | P43003 | 5/20 | 0.50 |
| ▸ | SLC1A2 | P43004 | 5/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.48 |
| ▸ | GRIK1 | P39086 | 4/20 | 0.46 |
| ▸ | GRIK2 | Q13002 | 4/20 | 0.46 |
| ▸ | GGT1 | P19440 | 2/20 | 0.46 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.46 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.46 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL393346 | 1.00 | SLC7A5 (0.56) | SLC7A5SLC1A1SLC1A3SLC1A2PTGS1 | |
| SCHEMBL4947418 | 1.00 | SLC7A5 (0.56) | SLC7A5SLC1A1SLC1A3SLC1A2PTGS1 | |
| SCHEMBL5819946 | 1.00 | SLC7A5 (0.56) | SLC7A5SLC1A1SLC1A3SLC1A2PTGS1 | |
| SCHEMBL5823952 | 1.00 | SLC7A5 (0.56) | SLC7A5SLC1A1SLC1A3SLC1A2PTGS1 | |
| SCHEMBL13746293 | 1.00 | SLC7A5 (0.56) | SLC7A5SLC1A1SLC1A3SLC1A2PTGS1 | |
| SCHEMBL196983 | 1.00 | SLC7A5 (0.56) | SLC7A5SLC1A1SLC1A3SLC1A2PTGS1 | |
| SCHEMBL1607862 | 1.00 | SLC7A5 (0.56) | SLC7A5SLC1A1SLC1A3SLC1A2PTGS1 | |
| SCHEMBL305904 | 1.00 | SLC7A5 (0.56) | SLC7A5SLC1A1SLC1A3SLC1A2PTGS1 | |
| SCHEMBL13753646 | 1.00 | SLC7A5 (0.56) | SLC7A5SLC1A1SLC1A3SLC1A2PTGS1 | |
| SCHEMBL3744052 | 0.84 | OR51E2 (0.42) | SLC7A5SLC1A1SLC1A3SLC1A2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140271926-A1 | METHODS OF USE OF GLUTAMINE SYNTHETASE INHIBITORS | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2014-09-18 | — | — | US | claimed |
| EP-1752143-A1 | Novel uses for drugs targeting glutamine synthetase | NewThera (FR) | 2007-02-14 | — | — | EP | claimed |
| US-20240043878-A1 | GENERATION OF A HIGH PRODUCING RECOMBINANT CHINESE HAMSTER OVARY CELL LINE FOR THERAPEUTIC PROTEIN PRODUCTION | SANOFI (FR) | 2024-02-08 | — | — | US | disclosed |
| EP-4214308-A1 | GENERATION OF A HIGH PRODUCING RECOMBINANT CHINESE HAMSTER OVARY CELL LINE FOR THERAPEUTIC PROTEIN PRODUCTION | Sanofi (FR) | 2023-07-26 | — | — | EP | disclosed |
| WO-2023069727-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF HYPERPROLIFERATIVE, INFLAMMATORY, AND IMMUNOLOGICAL DISEASES, AND INFECTIONS | EDISON ONCOLOGY (US) | 2023-04-27 | — | — | WO | disclosed |
| US-10947598-B2 | Methods for determining the metabolic status of lymphomas | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2021-03-16 | — | — | US | disclosed |
| EP-3356551-B1 | METHODS FOR DETERMINING THE METABOLIC STATUS OF B-LYMPHOMAS | INST NAT SANTE RECH MED (FR) | 2020-09-02 | — | — | EP | disclosed |
| US-20180282816-A1 | METHODS FOR DETERMINING THE METABOLIC STATUS OF LYMPHOMAS | Université Côte d'Azur (FR) | 2018-10-04 | — | — | US | disclosed |
| EP-3356551-A1 | METHODS FOR DETERMINING THE METABOLIC STATUS OF LYMPHOMAS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2018-08-08 | — | — | EP | disclosed |
| US-20140271926-A1 | METHODS OF USE OF GLUTAMINE SYNTHETASE INHIBITORS | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2014-09-18 | — | — | US | disclosed |
| WO-2012095514-A1 | RECOMBINANT PROTEIN PRODUCTION SYSTEM | VIVALIS (FR) | 2012-07-19 | — | — | WO | disclosed |
| US-20090209474-A1 | NOVEL USES FOR DRUGS TARGETING GLUTAMINE SYNTHETASE | NEWTHERA (FR) | 2009-08-20 | — | — | US | disclosed |
| EP-1965778-A2 | NOVEL USES FOR DRUGS TARGETING GLUTAMINE SYNTHETASE | NewThera (FR) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007017768-A2 | NOVEL USES FOR DRUGS TARGETING GLUTAMINE SYNTHETASE | NEWTHERA (FR) | 2007-02-15 | — | — | WO | disclosed |
| EP-1752143-A1 | Novel uses for drugs targeting glutamine synthetase | NewThera (FR) | 2007-02-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209474-A1 | NOVEL USES FOR DRUGS TARGETING GLUTAMINE SYNTHETASE | GLUL, GLS2, ASNS | SLC7A5 34/4885SLC1A1 26/4885SLC1A3 30/4885 |
| US-10947598-B2 | Methods for determining the metabolic status of lymphomas | GAPDH, GCDH, IDH2 | SLC7A5 1677/4885SLC1A1 1544/4885SLC1A3 1392/4885 |
| US-20240043878-A1 | GENERATION OF A HIGH PRODUCING RECOMBINANT CHINESE HAMSTER OVARY CELL LINE FOR THERAPEUTIC PROTEIN PRODUCTION | DHODH, GLUL, GLS2 | SLC7A5 434/4885SLC1A1 956/4885SLC1A3 825/4885 |
| US-20180282816-A1 | METHODS FOR DETERMINING THE METABOLIC STATUS OF LYMPHOMAS | GAPDH, IDH2, GCDH | SLC7A5 1709/4885SLC1A1 1258/4885SLC1A3 1318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.